Qiagen and Eli Lilly have signed an agreement to co-develop universal and modular assay panels for the simultaneous analysis of DNA and RNA biomarkers targeting multiple cellular pathways involved in common cancer types.
Under the collaboration, the companies will develop tests, which will be based on Qiagen’s Modaplex analysis platform. Qiagen claims that the multi-modal, multi-analyte Modaplex analysis platform can process multiple sample types and biomarkers in a single test.
Qiagen CEO Peer M Schatz said that the company is excited to add a new stage to its successful collaboration with Lilly, this time co-developing a broad panel of molecular assays covering a range of biomarkers with diverse nucleic acid analytes and modalities to guide the use of tailored therapies.
"Our collaborations with Lilly are among more than 20 co-development and co-commercialization projects underway with leading pharmaceutical and biotechnology companies," Schatz added.
The new collaboration is the fourth project in the two companies’ long-standing partnership.
Image: Eli Lilly and Company’s global headquarters, in Indianapolis, US. Photo: Courtesy of Guanaco152003